A New Gene Signature for Predicting Metastatic Outcomes in Breast Cancer
Author Information
Author(s): Yau Christina, Esserman Laura, Moore Dan H, Waldman Fred, Sninsky John, Benz Christopher C
Primary Institution: Buck Institute for Age Research
Hypothesis
Can a multigene signature improve the prediction of metastatic outcomes in early-stage hormone receptor-negative and triple-negative breast cancer?
Conclusion
The study identified a 14-gene signature that is superior in predicting metastatic outcomes compared to existing gene signatures.
Supporting Evidence
- A novel set of 14 prognostic gene candidates was identified as outcome predictors.
- The HRneg/Tneg gene signature index proved more accurate than any individual candidate gene.
- Significant positive correlations were observed between the HRneg/Tneg index and immune-related signatures.
- Network analysis identified 8 genes linked to immune/inflammatory chemokine regulation.
Takeaway
Researchers found a new set of genes that can help doctors predict if breast cancer will spread, which could help avoid unnecessary treatments for some patients.
Methodology
The study used a training cohort of 199 HRneg cases and a validation cohort of 75 HRneg cases to identify and validate a gene signature.
Limitations
The study's findings need further validation in independent cohorts.
Participant Demographics
The study included early-stage hormone receptor-negative and triple-negative breast cancer patients, with a significant portion being younger women and African-Americans.
Statistical Information
P-Value
6.2 × 10-7
Confidence Interval
95% CI 2.4 to 7.45
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website